Patients with L1CAM-expressing tumours had a 2.9 times higher risk of dying from their cancer than patients lacking L1CAM expression (HR 2.9, 95% CI 1.10 – 7.68) when corrected for the possible confounders lymph node metastasis, tumour size and TP53 mutations. This evidence concerns the gene TP53 and cancer.